The role of duloxetine in the treatment of anxiety disorders

Código QR

The role of duloxetine in the treatment of anxiety disorders

Domenico De Berardis1,2,3, Nicola Serroni2, Alessandro Carano1,4, Marco Scali1,4, Alessandro Valchera5, Daniela Campanella1,2, Alessandro D&rsquo;Albenzio1, Berardo Di Giuseppe2, Francesco Saverio Moschetta2, Rosa Maria Salerno1, Filippo Maria Ferro11Department of Oncology and Neurosciences,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Domenico De Berardis, Nicola Serroni, Alessandro Carano, Marco Scali, Alessandro Valchera, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a5df458efc8343dda82baca21994ae6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Duloxetine in the treatment of generalized anxiety disorder
por: Trevor R Norman, et al.
Publicado: (2009)

Duloxetine for the treatment of generalized anxiety disorder: a review
por: Ahsan Y Khan, et al.
Publicado: (2008)

Duloxetine in panic disorder with somatic gastric pain
por: Preve M, et al.
Publicado: (2013)

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
por: Michele Fornaro, et al.
Publicado: (2011)

Evidence to practice: treatment of anxiety in individuals with autism spectrum disorders
por: Russell Lang, et al.
Publicado: (2011)

New treatment options for fibromyalgia: critical appraisal of duloxetine
por: Nurcan &Uuml;&ccedil;eyler, et al.
Publicado: (2008)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Bernhard T Baune
Publicado: (2008)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018)

Pregabalin for the treatment of generalized anxiety disorder: an update
por: Baldwin DS, et al.
Publicado: (2013)

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada E, et al.
Publicado: (2015)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Carla M Canuso, et al.
Publicado: (2010)

Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders
por: Prasko J, et al.
Publicado: (2016)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada E, et al.
Publicado: (2016)

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
por: Levitan MN, et al.
Publicado: (2015)

Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
por: Fornaro M, et al.
Publicado: (2016)

Differential attentional bias in generalized anxiety disorder and panic disorder
por: Chen J, et al.
Publicado: (2013)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider M, et al.
Publicado: (2017)

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao K, et al.
Publicado: (2013)

Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
por: Atake K, et al.
Publicado: (2015)

Epilepsy and suicide: pathogenesis, risk factors, and prevention
por: Alberto Verrotti, et al.
Publicado: (2008)

The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders
por: Peedicayil J
Publicado: (2020)

Anxiety disorders and GABA neurotransmission: a disturbance of modulation
por: Nuss P
Publicado: (2015)

A review of neuroimaging studies of anxiety disorders in China
por: Chen J, et al.
Publicado: (2011)

Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment
por: G&eacute;rard A, et al.
Publicado: (2012)

Social anxiety disorder: A review of environmental risk factors
por: Christina A Brook, et al.
Publicado: (2008)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang J, et al.
Publicado: (2018)

Imitation and communication skills development in children with pervasive developmental disorders
por: Andrea De Giacomo, et al.
Publicado: (2009)

Transcranial magnetic stimulation for the treatment of anxiety disorder
por: Rodrigues PA, et al.
Publicado: (2019)

Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients
por: Zou C, et al.
Publicado: (2013)

Individual correlates of self-stigma in patients with anxiety disorders with and without comorbidities
por: Ociskova M, et al.
Publicado: (2015)

Movement Disorders Associated with COVID-19
por: Mehri Salari, et al.
Publicado: (2021)

An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis
por: Kuga A, et al.
Publicado: (2017)

SAFA: A new measure to evaluate psychiatric symptoms detected in a sample of children and adolescents affected by eating disorders. Correlations with risk factors
por: Emilo Franzoni, et al.
Publicado: (2009)

Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder
por: Tian-Xiang Zhang, et al.
Publicado: (2021)

Examining the effect of a wearable, anxiety detection technology on improving the awareness of anxiety signs in autism spectrum disorder: a pilot randomized controlled trial
por: Jenny Nguyen, et al.
Publicado: (2021)

Cognitive impairment in generalized anxiety disorder revealed by event-related potential N270
por: Yang Y, et al.
Publicado: (2015)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino J, et al.
Publicado: (2012)

Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study
por: Fontani V, et al.
Publicado: (2011)

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
por: Ariadna Laguna, et al.
Publicado: (2021)

Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
por: Jean-Michel Azorin, et al.
Publicado: (2010)